Vaccine antigen protein

Vaccine antigen proteins are the primary immunogenic components of vaccines, designed to elicit a specific and protective immune response against a pathogen or diseased cell. These proteins are typically derived from the surface of viruses or bacteria, such as the Spike protein of SARS-CoV-2, or are engineered as recombinant proteins to represent specific epitopes (NIH/NIAID, 2023). Once introduced into the body, they are recognized by the immune system as foreign, triggering the production of antibodies and the activation of T-cells. This process establishes immunological memory, allowing the host to respond more rapidly and effectively upon subsequent exposure to the actual pathogen. In addition to infectious diseases, vaccine antigens are increasingly being developed for cancer immunotherapy to target tumor-specific antigens or neoantigens (Nature, 2022). The efficacy of these proteins often depends on their structural integrity and the presence of appropriate adjuvants to enhance the immune response. As a target entry, this term is considered a broad category rather than a specific molecular target.

Other names

ImmunogenVaccine antigenAntigenic proteinProtective antigenRecombinant vaccine protein

Vaccine antigen proteins function by mimicking pathogen-specific components to educate the host immune system without causing disease. Upon administration, these proteins are captured by professional antigen-presenting cells (APCs), such as dendritic cells, and processed into peptides for presentation on Major Histocompatibility Complex (MHC) molecules (Pollard & Bijker, 2021, Nature Reviews Immunology). This presentation triggers the activation of helper T-cells and cytotoxic T-cells, while intact antigens interact directly with B-cell receptors to stimulate the production of high-affinity neutralizing antibodies (WHO, 2020).